Contributions
Abstract: P501
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Imaging
Background: Cerebral microbleeds (CMBs) are associated with aging and neurodegenerative disorders. The prevalence of CMBs has not previously been well established in the multiple sclerosis (MS) literature.
Objective: To assess CMB prevalence in MS and clinically isolated syndrome (CIS) patients, and explore their association with clinical outcomes.
Methods: 445 MS patients (266 relapsing-remitting, 138 secondary-progressive and 41 primary-progressive), 45 CIS patients, 51 patients with other neurologic diseases and 177 healthy controls (HCs) were assessed by 3T MRI and clinical examinations. A subset of 168 MS patients and 50 HCs underwent neuropsychological testing. CMB number was assessed on susceptibility-weighted minimum intensity projections using the Microbleed Anatomical Rating Scale, while volume was calculated using quantitative susceptibility maps. Differences between the groups were analyzed using the chi-square, Fisher"s exact test, Student"s t-test and analysis of variance, while the associations of CMBs with clinical and other MRI outcomes were explored using correlation and regression analyses. Because frequency of CMBs increases with age, we investigated their prevalence separately in subjects ≥50 or < 50 years old.
Results: In a correlation analysis, increased number of CMBs was significantly associated with deteriorated auditory/verbal learning and memory (p=0.006), and visual information-processing speed trending (p=0.049) in MS patients. In regression analysis, adjusted for age, hypertension and normalized brain volume, an increased number of CMBs was significantly associated with increased physical disability in MS population (R2=0.23, p< 0.0001). Significantly more MS patients had CMBs compared to HCs (19.8% vs. 7.4%, p=0.01) in ≥50 years old age group. A trend for greater presence of CMBs was found in MS patients (p=0.016), and in CIS patients < 50 years old (p=0.039), compared to HCs.
Conclusions: Monitoring CMBs may be relevant in MS and CIS patients at higher risk for developing cognitive and physical disability.
Disclosure:
Funding statement:
This study was funded with internal resources of the Buffalo Neuroimaging Analysis Center. In addition, we received support from the Jacquemin Family Foundation.
Collective disclosure statement:
Robert Zivadinov received personal compensation from Teva Pharmaceuticals, Biogen Idec, EMD Serono, Genzyme-Sanofi, Claret Medical, IMS Health and Novartis for speaking and consultant fees. He received financial support for research activities from Teva Pharmaceuticals, Genzyme-Sanofi, Novartis, Claret Medical, Intekrin-Coherus and IMS Health.
Deepa P. Ramasamay, Paul Polak, Jesper Hagemeier, Christopher Magnano, Niels Bergsland, Nicola Bertolino, David Utrianen and Ferdinand Schweser have nothing to disclose.
Michael G. Dwyer has received consultant fees from Claret Medical and EMD Serono.
Bianca Weinstock- Guttman received honoraria as a speaker and as a consultant for Biogen Idec, Teva Pharmaceuticals, EMD Serono, Genzyme&Sanofi, Novartis and Acorda. Dr Weinstock-Guttman received research funds from Biogen Idec, Teva Pharmaceuticals, EMD Serono, Genzyme&Sanofi, Novartis, Acorda.
Channa Kolb has received speaker honoraria from Novartis, Genzyme and Biogen-Idec.
Ralph RH.. Benedict has acted as a consultant or scientific advisory board member for Bayer, Biogen Idec, Actelion, and Novartis. He receives royalties from Psychological Assessment Resources, Inc. He has received financial support for research activities from Shire Pharmaceuticals, Accorda and Biogen Idec.
David Hojnacki has received speaker honoraria and consultant fees from Biogen Idec, Teva Pharmaceutical Industries Ltd., EMD Serono, Pfizer Inc, and Novartis.
E. Mark Haacke is the president of Magnetic Resonance Innovations, Inc.
Abstract: P501
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Imaging
Background: Cerebral microbleeds (CMBs) are associated with aging and neurodegenerative disorders. The prevalence of CMBs has not previously been well established in the multiple sclerosis (MS) literature.
Objective: To assess CMB prevalence in MS and clinically isolated syndrome (CIS) patients, and explore their association with clinical outcomes.
Methods: 445 MS patients (266 relapsing-remitting, 138 secondary-progressive and 41 primary-progressive), 45 CIS patients, 51 patients with other neurologic diseases and 177 healthy controls (HCs) were assessed by 3T MRI and clinical examinations. A subset of 168 MS patients and 50 HCs underwent neuropsychological testing. CMB number was assessed on susceptibility-weighted minimum intensity projections using the Microbleed Anatomical Rating Scale, while volume was calculated using quantitative susceptibility maps. Differences between the groups were analyzed using the chi-square, Fisher"s exact test, Student"s t-test and analysis of variance, while the associations of CMBs with clinical and other MRI outcomes were explored using correlation and regression analyses. Because frequency of CMBs increases with age, we investigated their prevalence separately in subjects ≥50 or < 50 years old.
Results: In a correlation analysis, increased number of CMBs was significantly associated with deteriorated auditory/verbal learning and memory (p=0.006), and visual information-processing speed trending (p=0.049) in MS patients. In regression analysis, adjusted for age, hypertension and normalized brain volume, an increased number of CMBs was significantly associated with increased physical disability in MS population (R2=0.23, p< 0.0001). Significantly more MS patients had CMBs compared to HCs (19.8% vs. 7.4%, p=0.01) in ≥50 years old age group. A trend for greater presence of CMBs was found in MS patients (p=0.016), and in CIS patients < 50 years old (p=0.039), compared to HCs.
Conclusions: Monitoring CMBs may be relevant in MS and CIS patients at higher risk for developing cognitive and physical disability.
Disclosure:
Funding statement:
This study was funded with internal resources of the Buffalo Neuroimaging Analysis Center. In addition, we received support from the Jacquemin Family Foundation.
Collective disclosure statement:
Robert Zivadinov received personal compensation from Teva Pharmaceuticals, Biogen Idec, EMD Serono, Genzyme-Sanofi, Claret Medical, IMS Health and Novartis for speaking and consultant fees. He received financial support for research activities from Teva Pharmaceuticals, Genzyme-Sanofi, Novartis, Claret Medical, Intekrin-Coherus and IMS Health.
Deepa P. Ramasamay, Paul Polak, Jesper Hagemeier, Christopher Magnano, Niels Bergsland, Nicola Bertolino, David Utrianen and Ferdinand Schweser have nothing to disclose.
Michael G. Dwyer has received consultant fees from Claret Medical and EMD Serono.
Bianca Weinstock- Guttman received honoraria as a speaker and as a consultant for Biogen Idec, Teva Pharmaceuticals, EMD Serono, Genzyme&Sanofi, Novartis and Acorda. Dr Weinstock-Guttman received research funds from Biogen Idec, Teva Pharmaceuticals, EMD Serono, Genzyme&Sanofi, Novartis, Acorda.
Channa Kolb has received speaker honoraria from Novartis, Genzyme and Biogen-Idec.
Ralph RH.. Benedict has acted as a consultant or scientific advisory board member for Bayer, Biogen Idec, Actelion, and Novartis. He receives royalties from Psychological Assessment Resources, Inc. He has received financial support for research activities from Shire Pharmaceuticals, Accorda and Biogen Idec.
David Hojnacki has received speaker honoraria and consultant fees from Biogen Idec, Teva Pharmaceutical Industries Ltd., EMD Serono, Pfizer Inc, and Novartis.
E. Mark Haacke is the president of Magnetic Resonance Innovations, Inc.